MET pathway as a therapeutic target
- PMID: 19333071
- PMCID: PMC2664527
- DOI: 10.1097/JTO.0b013e31819d6f91
MET pathway as a therapeutic target
Abstract
Dysregulation of mesenchymal-epithelial transition factor receptor tyrosine kinase pathway leads to cell proliferation, protection from apoptosis, angiogenesis, invasion, and metastasis. It can be dysregulated through overexpression, constitutive activation, gene amplification, ligand-dependent activation or mutation. New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results.
Figures

Similar articles
-
Inhibition of HGF/MET as therapy for malignancy.Expert Opin Ther Targets. 2009 May;13(5):569-81. doi: 10.1517/14728220902853917. Expert Opin Ther Targets. 2009. PMID: 19397476 Review.
-
RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.Cancer Res. 2004 Nov 1;64(21):7962-70. doi: 10.1158/0008-5472.CAN-04-1043. Cancer Res. 2004. PMID: 15520203
-
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.Cancer Res. 2007 Mar 1;67(5):2081-8. doi: 10.1158/0008-5472.CAN-06-3495. Cancer Res. 2007. PMID: 17332337
-
The function, proteolytic processing, and histopathology of Met in cancer.Adv Cancer Res. 2009;103:1-23. doi: 10.1016/S0065-230X(09)03001-2. Adv Cancer Res. 2009. PMID: 19854350 Review.
-
MET receptor tyrosine kinase as a therapeutic anticancer target.Cancer Lett. 2009 Jul 18;280(1):1-14. doi: 10.1016/j.canlet.2008.10.045. Epub 2008 Dec 18. Cancer Lett. 2009. PMID: 19100682 Review.
Cited by
-
The METeoric rise of MET in lung cancer.Cancer. 2020 Nov 15;126(22):4826-4837. doi: 10.1002/cncr.33159. Epub 2020 Sep 5. Cancer. 2020. PMID: 32888330 Free PMC article. Review.
-
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.Invest New Drugs. 2012 Feb;30(1):327-34. doi: 10.1007/s10637-010-9536-x. Epub 2010 Sep 15. Invest New Drugs. 2012. PMID: 20842406 Clinical Trial.
-
Gastrointestinal health and nutritional strategies in autism spectrum disorder.J Gastroenterol. 2025 Aug;60(8):933-946. doi: 10.1007/s00535-025-02269-1. Epub 2025 Jun 18. J Gastroenterol. 2025. PMID: 40531376 Free PMC article. Review.
-
Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomark Res. 2024 Feb 12;12(1):24. doi: 10.1186/s40364-024-00566-0. Biomark Res. 2024. PMID: 38347643 Free PMC article. Review.
-
Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review.
References
-
- Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–804. - PubMed
-
- Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 1991;6:1997–2003. - PubMed
-
- Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 2007;213:316–325. - PubMed
-
- Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007;9:102–108. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous